| Literature DB >> 24533215 |
Maria Del Ben1, Francesco Angelico1, Roberto Cangemi1, Lorenzo Loffredo1, Roberto Carnevale1, Teresa Augelletti1, Francesco Baratta1, Licia Polimeni1, Pasquale Pignatelli1, Francesco Violi1.
Abstract
Background. Oxidative stress is enhanced in metabolic syndrome (MetS) and believed to contribute to accelerated atherosclerosis. Weight loss is associated with lowered oxidative stress. Methods. We performed a cross-sectional study in 92 consecutive patients with metabolic syndrome and 80 without. A dietary intervention with moderately low-calorie diet (600 calories/day negative energy balance) was carried out in 53 of metabolic syndrome patients. Oxidative stress, assessed by sNOX2-dp and urinary 8-iso-PGF2α, and antioxidant status, assessed by serum levels of vitamin E and adiponectin, were measured before and after 6 months. Results. Serum vitamin E/cholesterol ratio was significantly lower in metabolic syndrome compared to controls (P < 0.001) and decreased by increasing the number of metabolic syndrome components (P < 0.001). After six months, 23 and 30 patients showed >5% (group A) or <5% (group B) weight loss, respectively. Urinary 8-iso-PGF2α (-39.0%), serum sNOX2-dp (-22.2%), adiponectin (+125%), and vitamin E/cholesterol ratio (+129.8%) significantly changed only in A group. Changes in body weight and in serum adiponectin were independent predictors of vitamin E/cholesterol ratio variation. Conclusion. Our findings show that in metabolic syndrome moderate weight loss is associated with multiple health benefits including not only oxidative stress reduction but also enhancement of antioxidant status.Entities:
Year: 2012 PMID: 24533215 PMCID: PMC3914258 DOI: 10.5402/2012/960427
Source DB: PubMed Journal: ISRN Obes ISSN: 2090-9446
Clinical characteristics of patients with and without metabolic syndrome.
| Variables | Metabolic syndrome | Controls |
|
|---|---|---|---|
|
|
| ||
| Age (yr)* | 55 ± 10.9 | 54.12 ± 11.75 | n.s. |
| Gender, M/F | 57/35 | 47/33 | n.s. |
| High blood pressure** | 90% ( | 20% ( | <0.001 |
| Hypertriglyceridemia** | 68% ( | 12% ( | <0.001 |
| Hyperglycaemia** | 43% ( | 6% ( | <0.001 |
| Low HDL cholesterol** | 58% ( | 31% ( | <0.001 |
| Central obesity** | 94% ( | 16% ( | <0.001 |
| Total cholesterol, mg/dL* | 227 ± 53 | 190 ± 34 | <0.001 |
| HDL cholesterol, mg/dL* | 45.4 ± 12.4 | 50.6 ± 14.3 | 0.01 |
| Triglyceridemia,*** | 155 | 102.0 | <0.001 |
| Vitamin E/cholesterol ratio | 4.5 ± 1.2 | 5.2 ± 0.8 | <0.001 |
| Vitamin E | 26.0 ± 6.7 | 25.4 ± 5.4 | n.s. |
| Diabetes | 22% ( | 1% ( | <0.001 |
*Data are expressed as mean ± SD;
**Defined according to modified ATPIII criteria [4];
***Median and interquartile range.
Figure 1Mean serum vitamin E/cholesterol ratio according to the number of components of metabolic syndrome. Distribution of vitamin E/cholesterol (P for trend <0.001) according to presence of 0, 1, 2, 3, 4, or 5 components of metabolic syndrome. Box plots demonstrate median, 25th, and 75th percentile values. Cells report means ± SD.
Clinical characteristics of patients with serum vitamin E/cholesterol ratio < or ≥5.
| Variables | Vitamin E/cholesterol ratio <5 ( | Vitamin E/cholesterol ratio ≥5 ( |
|
|---|---|---|---|
| Metabolic syndrome | 64% ( | 38% ( | 0.001 |
| Age (yr)* | 54.7 ± 10.6 | 54.4 ± 12.3 | n.s. |
| Gender, M/F | 63/38 | 41/30 | n.s. |
| High blood pressure** | 69% ( | 41% ( | <0.001 |
| Hypertriglyceridemia** | 49% ( | 31% ( | 0.019 |
| Hyperglycaemia** | 41% ( | 14% ( | <0.001 |
| Low HDL cholesterol** | 51% ( | 35% ( | 0.043 |
| Central obesity** | 69% ( | 41% ( | <0.001 |
| Diabetes | 17% ( | 6% ( | 0.033 |
*Data are expressed as mean ± S D; **Defined according to modified ATPIII criteria [4].
Baseline values of some nutritional, anthropometric, and biochemical characteristics of the study participants and changes after 6 months of low-calorie, low-fat diet according to body weight reduction: group A ≥5%; group B <5%.
|
Variables | Group A | Group B | Between-groups comparison | |||||
|---|---|---|---|---|---|---|---|---|
| Body weight reduction ≥5%, | Body weight reduction <5%, | of change | ||||||
| Baseline | 6 months | Δ% | Baseline | 6 months | Δ% | Difference (95% CI) |
| |
| Total energy (Kcal) | 2801 ± 573 | 2156 ± 364*** | −23.0 | 2952 ± 405 | 2870 ± 455 | −2.7 | −562 (−750 to −374) | <.001 |
| Total fat (g) | 131.0 ± 28.9 | 87.4 ± 20.9*** | −33.2 | 133.4 ± 24.5 | 126.7 ± 25.5 | −5.0 | −36.8 (−53.1 to −20.5) | <.001 |
| Saturated fat (g) | 37.8 ± 10.1 | 25.2 ± 6.0*** | −33.0 | 41.7 ± 7.2 | 39.7 ± 8.4 | −4.5 | −10.6 (−16.0 to −5.1) | <.001 |
| Monounsaturated fat (g) | 77.0 ± 18.2 | 50.0 ± 14.4*** | −35.0 | 74.8 ± 17.1 | 70.7 ± 16.3 | −5.3 | −22.9 (−43.1 to −11.8) | <.001 |
| Polyunsaturated fat (g) | 11.8 ± 2.3 | 8.6 ± 2.0*** | −26.2 | 11.4 ± 2.4 | 11.2 ± 2.3 | −1.7 | −2.8 (−4.2 to −1.5) | <.001 |
| Oil/seasoning fat (teasp/wk) | 147.4 ± 50.2§ | 60.9 ± 11.0*** | −58.6 | 182.0 ± 32.4 | 177.3 ± 36.1 | −2.5 | −81.8 (−108.2 to −55.4) | <.001 |
| Body weight, (kg) | 96.05 ± 18.3 | 89.5 ± 17.6*** | −6.8 | 98.7 ± 18.2 | 98.8 ± 18.2 | +0.1 | −6.6 (−8.1 to −5.0) | <.001 |
| Urinary 8-isoprostanes | 144.1 ± 55.3 | 87.8 ± 53.6** | −39.0 | 124.5 ± 63.3 | 119.6 ± 58.9 | −3.9 | −51.3 (−99.0 to −3.6) | .035 |
| sNOX2-dp (pg/mL) | 42.2 ± 22.7 | 32.8 ± 24.6* | −22.2 | 45.0 ± 17.0 | 41.0 ± 17.5 | −8.8 | −20.2 (−34.5 to 5.9) | <.01 |
| Adiponectin (ng/mg) | 4.3 ± 1.0 | 9.7 ± 1.9*** | +125.5 | 4.5 ± 1.0 | 5.1 ± 1.3 | 13.3 | +4.8 (3.6 to 6.0) | <.01 |
| Vitamin E ( | 21.4 ± 7.3 | 35.2 ± 8.4*** | +100.2 | 17.3 ± 5.6 | 17.6 ± 5.4 | +4.3 | −95.4 (−150.8 to 41.0) | <.001 |
| Cholesterol ( | 5.6 ± 1.0 | 4.8 ± 0.9** | −13.0 | 5.4 ± 0.8 | 5.4 ± 0.6 | −0.1 | 13.1 (6.7 to 19.6) | <.001 |
| Vitamin E/cholesterol ratio | 4.8 ± 1.7 | 9.4 ± 2.9*** | +129.8 | 4.3 ± 1.0 | 4.1 ± 1.2 | +5.4 | +4.8 (3.5 to 6.1) | <.001 |
*P < .05; **P < .01; ***P < .001, 6 months versus baseline.
§ P < .05 versus group B at baseline.
Statistical analysis was performed by t-test (for between-groups analysis) and paired t-test (for within-group analysis).
Correlations between changes in serum vitamin/cholesterol ratio and changes of some nutritional, antropometric, metabolic and oxidative stress parameters.
| Vitamin | Weight | BMI | Waist | Total | Fat | Oil | Blood | HOMA-IR | Tot. | Trigl. | Adipo. | NOX2 | Urinary 8-iso-PGF2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitamin E/chol. ratio | 1.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Weight (kg) | −.67** | 1.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| BMI | −.66** | .98*** | 1.00 | — | — | — | — | — | — | — | — | — | — | — |
| Waist circle (cm) | −.40** | .73*** | .77*** | 1.00 | — | — | — | — | — | — | — | — | — | — |
| Total calories | −.63*** | .87*** | .86*** | .60*** | 1.00 | — | — | — | — | — | — | — | — | — |
| Fat calories | −.40** | .58*** | .57*** | .39** | .67*** | 1.00 | — | — | — | — | — | — | — | — |
| Dietary oil intake (tablesp/day) | −.59*** | .75*** | .76*** | .53*** | .74*** | .60*** | 1.00 | — | — | — | — | — | — | — |
| Blood glucose (mg/dL) | −.38** | .45*** | .47*** | .47*** | .37** | −.03 | .49*** | 1.00 | — | — | — | — | — | — |
| HOMA-IR | −.27* | .34* | .37** | .25 | .20 | −.02 | .24 | .41** | 1.00 | — | — | — | — | — |
| Total cholesterol (mg/dL) | −.60* | .57*** | .58*** | .46*** | .60*** | .37** | .46** | .23 | .31* | 1.00 | — | — | — | — |
| Triglycerides (mg/dL) | −.31* | .36** | .34* | .26 | .31* | .10 | .24 | .14 | .30* | .56*** | 1.00 | — | — | — |
| Adiponectin (ng/mg) | .44** | −.52*** | −.49*** | −.40*** | −.39** | −.29* | −.45*** | −.31* | −.06 | −.363** | −.07 | 1.00 | — | — |
| sNOX2-dp (pg/mL) | −.13 | .30* | .27* | .21 | .25 | .07 | .17 | .26 | .11 | -.01 | −.07 | .38*** | 1.00 | — |
| Urinary 8-iso-PGF2 | −.14 | .31* | .29* | .31* | .26 | .09 | .15 | .17 | .22 | .07 | −.07 | −.43*** | .63*** | 1.00 |
*P < .05; **P < .01; ***P < .001.